Plus   Neg

VF Corp. Withdraws FY20 Outlook - Quick Facts

VF Corp. (VFC) has decided to withdraw its adjusted fiscal 2020 outlook as a result of the disruption and uncertainty caused by COVID-19. The company will provide more information during the fourth quarter conference call in May 2020.

As a precautionary measure, VF Corp. has elected to draw down $1 billion from its revolving credit facility. This funds the company's expected working capital requirements through the first half of fiscal 2021. The company said these additional actions will preserve financial liquidity and flexibility.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT